Expression of Foxp3 in Colorectal Cancer but Not in Treg Cells Correlates with Disease Progression in Patients with Colorectal Cancer

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Kim, Mia ^a   Grimmig, Tanja ^a   Grimm, Martin ^b   Lazariotou, Maria ^a   Meier, Eva ^a   Rosenwald, Andreas ^a   Tsaur, Igor ^c   Blaheta, Roman ^c   Heemann, Uwe ^d   Germer, Christoph Thomas ^a   Waaga Gasser, Ana Maria ^a   Gasser, Martin ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INFILTRATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CD25 GENE; CD4 GENE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FOXP3 GENE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; INTERLEUKIN 10 GENE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA GENE;

AGED; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, REGULATORY;

EID: 84873822300     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053630     Document Type: Article

References (33)

1. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, et al. (2005) Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22: 329-341.
2. Weiner HL, (2001) Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 182: 207-214.
3. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, et al. (1997) A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389: 737-742.
4. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, et al. (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102: 18538-18543.
5. Hiraoka N, Onozato K, Kosuge T, Hirohashi S, (2006) Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12: 5423-5434.
6. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, et al. (2007) FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 13: 902-911.
7. Zou W, (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295-307.
8. Loddenkemper C, Schernus M, Noutsias M, Stein H, Thiel E, et al. (2006) In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. J Transl Med 4: 52.
9. Salama P, Phillips M, Grieu F, Morris M, Zeps N, et al. (2008) Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer. J Clin Oncol 27: 186-192.
10. Tao H, Mimura Y, Aoe K, Kobayashi S, Yamamoto H, et al. (2012) Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer 75: 95-101.
11. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, et al. (2009) FOXP3 expression and overall survival in breast cancer. J Clin Oncol 27: 1746-1752.
12. Ladoire S, Arnould L, Mignot G, Coudert B, Rebe C, et al. (2011) Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 125: 65-72.
13. Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grussel S, et al. (2007) Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 67: 8344-8350.
14. Wang WH, Jiang CL, Yan W, Zhang YH, Yang JT, et al. (2010) FOXP3 expression and clinical characteristics of hepatocellular carcinoma. World J Gastroenterol. 16: 5502-5509.
15. Winerdal ME, Marits P, Winerdal M, Hasan M, Rosenblatt R, et al. (2011) FOXP3 and survival in urinary bladder cancer. BJU Int 108: 1672-1678.
16. Ebert LM, Tan BS, Browning J, Svobodova S, Russell SE, et al. (2008) The regulatory T cell-associated transcription factor Foxp3 is expressed by tumor cells. Cancer Res 68: 3001-3009.
17. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, et al. (2003) Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9: 4404-4408.
18. Yu P, Lee Y, Liu W, Krausz T, Chong A, et al. (2005) Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 201: 779-791.
19. Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, et al. (2004) Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173: 1444-1453.
20. Alvaro T, Lejeune M, Salvado MT, Bosch R, García JF, et al. (2005) Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 11: 1467-1473.
21. Lee WS, Park S, Lee WY, Yun SH, Chun HK, (2010) Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer. Cancer 116: 5188-5199.
22. Correale P, Rotundo MS, Del Vecchio MT, Remondo C, Migali C, et al. (2010) Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother 33: 435-441.
23. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, et al. (2009) Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 137: 1270-1279.
24. Suzuki H, Chikazawa N, Tasaka T, Wada J, Yamasaki A, et al. (2010) Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol Immunother 59: 653-661.
25. Whiteside TL, (2006) The role of immune cells in the tumor microenvironment. Cancer Treat Res 130: 103-124.
26. Lu H, Ouyang W, Huang C, (2006) Inflammation, a key event in cancer development. Mol Cancer Res 4: 221-233.
27. Shimizu J, Yamazaki S, Sakaguchi S, (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163: 5211-5218.
28. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, et al. (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59: 3128-3133.
29. Chaput N, Louafi S, Bardier A, Charlotte F, Vaillant JC, et al. (2008) Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 58: 520-529.
30. Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules G, et al. (2008) Foxp3 expression in human cancer cells. J Transl Med 6: 19.
31. Greene FL, (2003) TNM staging for malignancies of the digestive tract: (2003) changes and beyond. Semin Surg Oncol 21: 23-29.
32. Sack MJ, Roberts SA, (1997) Cytokeratins 20 and 7 in the differential diagnosis of metastatic carcinoma in cytologic specimens. Diagn Cytopathol 16: 132-136.
33. Ho-Pun-Cheung A, Bascoul-Mollevi C, Assenat E, Bibeau F, Boissière-Michot F, et al. (2009) Validation of an appropriate reference gene for normalization of reverse transcription-quantitative polymerase chain reaction data from rectal cancer biopsies. Anal Biochem 388: 348-350.